In the News
Wall Street Journal Covers GNS Launch of Gemini
This is the first AI-based virtual patient for multiple myeloma, said Colin Hill, the Cambridge, Mass.-based company’s co-founder and chief executive. It is traditionally difficult to predict how specific drugs or combinations of drugs might help individual multiple...
read more
Cambia’s Peggy Maguire: Palliative Care Supports Economic Sustainability
Peggy Maguire, president of Cambia Health Foundation, shares how Cambia worked with GNS to use predictive analytics and identify members of Cambia's Medicare Advantage population that could benefit from an extra layer of support. Read the full article here.
read more
WebMD discusses the impact of AI on healthcare
"The company Hill runs, GNS Healthcare, found a genetic signature in some multiple myeloma patients that suggested they would benefit from a transplant. For others, the risky, painful, and expensive procedure would probably only provide false hope." Read more here.
read more
Study: If more Wisconsin doctors provided better care, key medical procedures would cost 30% less
The Milwaukee Journal Sentinel covers the results of a collaboration between the Wisconsin Business Group on Health and GNS Healthcare in identifying the impact of provider optimization on cost. Read the article!
read more
Harvard Business Review: Using AI to Understand What Causes Diseases
Sema Sgaier and Francesca Domini of Surgo Foundation share how they causal AI can bring new clarity to understanding the underlying cause of disease. Read the full article here.
read more
Cigna Invests In GNS Healthcare Precision Medicine Venture
Forbes contributor Bruce Japsen notes that the Cigna investment "fits the effort by health insurance companies to use claims data and related patient health information to better target illness and provide more cost-effective and high quality patient care. These...
read more
GNS Among Ways Amgen is Applying AI to Combat Serious Illness
Wired magazine dove in to a few approaches Amgen is taking to using AI to combat serious illness and one of those ways is by partnering with GNS! Amgen, the world's largest independent biotech company, is leading the charge in combining life sciences with data and...
read more
Iya Khalil weighs in on AI in Real-World Drug Discovery
Following the recent Bio-IT conference, Iya Khalil and fellow keynote panelists weigh in on how AI is impacting real-world drug discovery efforts. Read the full article here.
read more
GNS CEO Colin Hill joins rank of Top 50 Healthcare Technology CEOs of 2019
The Healthcare Technology Report evaluates the hundreds of CEOs that lead exemplary organizations in the fields of medical devices, biotech, healthcare analytics, healthcare software and other related areas. They gather data on each nominee’s professional background...
read more
Adding Artificial Intelligence to Drug Discovery – Iya Khalil interviewed by GEN News
"AI is being used to really leverage learning from large-scale datasets, and those large-scale datasets are used to get to better novel targets." - Iya Khalil, GNS Co-Founder and COO, joins Mike May of Genetic Engineering & Biotechnology News to discuss AI in drug...
read more